USP 800 Hazardous Drug Handling Guide
Hazardous drugs are essential in modern healthcare, particularly in oncology and other specialized therapies, but occupational exposure can create risks for pharmacists, technicians, nurses, physicians, environmental services personnel, and others who work around these medicines.
USP 800 hazardous drug handling requirements establish a structured approach for reducing those risks. USP General Chapter <800> covers hazardous drugs throughout their lifecycle in a healthcare setting, including receiving, storage, preparation, compounding, dispensing, administration, transport, cleaning, and disposal. It applies to both sterile and nonsterile hazardous drug preparations and to healthcare personnel and organizations involved in these activities.
The chapter goes beyond protective equipment. It requires healthcare organizations to build hazardous-drug controls into their occupational safety system through a current hazardous-drug list, appropriate facilities, engineering controls, trained personnel, safe work practices, suitable PPE, and controlled waste disposal.
What Is USP 800?
USP <800> is a healthcare safety standard addressing how hazardous drugs should be handled to protect personnel, patients, and the environment from unnecessary exposure.
Its scope extends across the hazardous-drug workflow rather than focusing only on pharmacy compounding. The chapter addresses receiving and unpacking, storage, compounding, dispensing, administration, environmental control, spill response, waste disposal, documentation, training, and medical surveillance.
Organizations working within broader pharmaceutical quality systems should integrate hazardous-drug procedures into established cGMP and SOP systems where applicable.
USP 800 Hazardous Drug Handling Requirements
A practical USP <800> program can be understood as several connected layers of control.
| Control Area | Main Objective |
|---|---|
| Hazardous-drug identification | Determine which products require hazardous-drug controls |
| Risk assessment | Evaluate dosage form, manipulation, packaging, and exposure potential |
| Facility design | Contain contamination through ventilation and pressure controls |
| Engineering controls | Capture hazardous particles, aerosols, and residues |
| PPE | Provide a barrier between personnel and hazardous materials |
| Work practices | Reduce generation and spread of contamination |
| Environmental monitoring | Check whether containment remains effective |
| Training | Confirm personnel can safely perform assigned tasks |
| Cleaning and decontamination | Remove or deactivate hazardous residues |
| Spill response | Control unexpected hazardous-drug releases |
| Documentation | Demonstrate consistent implementation |
| Medical surveillance | Support occupational health monitoring |
Identifying Hazardous Drugs
USP <800> uses the hazardous-drug framework maintained by the National Institute for Occupational Safety and Health (NIOSH). An organization handling hazardous drugs must maintain its own list covering hazardous drugs actually handled by the entity.
The list should be reviewed at least every 12 months. A newly introduced drug or dosage form should also be assessed when it enters the organization.
Assessment of Risk
Not every hazardous-drug dosage form creates the same occupational exposure potential. An intact tablet may present less direct exposure risk than a tablet being crushed, a capsule being opened, a powder being weighed, or an injectable hazardous drug being manipulated.
Where applicable, an assessment of risk considers:
- type of hazardous drug;
- dosage form;
- risk of exposure;
- packaging; and
- degree of manipulation.
If alternative containment strategies are selected through an assessment of risk, the decision and work practices should be documented and reviewed at least annually.
How Hazardous Drug Exposure Can Occur
Hazardous drugs can unintentionally enter the body through skin or mucosal contact, inhalation, injection, or ingestion. Exposure is not limited to compounding because contaminated containers and surfaces may also create risk.
Potential exposure activities include receiving contaminated containers, counting or repackaging tablets, crushing tablets, opening capsules, weighing powders, reconstituting drugs, withdrawing injectable preparations, handling contaminated PPE, administration, spill cleanup, patient-care activities, transportation, and waste handling.
Responsibilities of the Designated Person
Each organization handling hazardous drugs should have a qualified, trained person responsible for oversight of the hazardous-drug program.
The designated person may oversee procedures, personnel competency, facility controls, environmental monitoring, testing records, corrective actions, and ongoing compliance.
Records generated from these activities should follow reliable data-integrity principles such as ALCOA+.
Facilities and Engineering Controls
Hazardous-drug areas should be designed to support worker, patient, and environmental safety. Access should be limited to authorized personnel, suitable hazard signage should be displayed, and HD areas should be separated from breakrooms and similar locations.
Receiving and Unpacking
Antineoplastic hazardous drugs and hazardous-drug APIs should be unpacked in a neutral or negative-pressure area relative to surrounding spaces. They should not be unpacked from external shipping containers in sterile compounding or positive-pressure areas.
Hazardous Drug Storage
Hazardous drugs should be stored in a way that reduces breakage and spills. Antineoplastic hazardous drugs requiring manipulation beyond simple counting or repackaging, together with hazardous-drug APIs, require controlled storage designed to reduce occupational exposure and cross-contamination.
The chapter specifies an externally ventilated, negative-pressure room with at least 12 air changes per hour (ACPH) for applicable storage conditions.
C-PEC and C-SEC Requirements
C-PEC — Containment Primary Engineering Control: The ventilated device in which hazardous drugs are directly manipulated.
C-SEC — Containment Secondary Engineering Control: The room in which the C-PEC is installed.
For hazardous-drug compounding, the C-PEC operates within an appropriate C-SEC. The C-SEC is externally vented, physically separated from other preparation areas, and maintained at suitable air exchange and negative pressure.
Applicable hazardous-drug compounding areas use a negative-pressure differential of approximately 0.01 to 0.03 inches of water column relative to adjacent areas.
Nonsterile Hazardous Drug Compounding
Suitable C-PECs for nonsterile hazardous-drug compounding may include a containment ventilated enclosure, Class I or suitable Class II biological safety cabinet, or appropriate isolator depending on the activity.
The associated C-SEC requires at least 12 ACPH and suitable negative pressure. Surfaces should be smooth, impervious, non-shedding, and easy to clean.
Sterile Hazardous Drug Compounding
Sterile hazardous-drug compounding requires controls for both containment and microbial contamination. The C-PEC used for sterile HD manipulation must be externally vented and provide ISO Class 5 or better air quality.
| Sterile HD Arrangement | Air Change Requirement |
|---|---|
| ISO Class 7 buffer room with ISO Class 7 ante-room | Minimum 30 ACPH |
| Unclassified C-SCA | Minimum 12 ACPH |
For organizations applying a formal equipment and facility lifecycle, concepts such as URS, DQ, IQ, OQ, and PQ can provide a useful project framework.
Closed-System Drug-Transfer Devices
A closed-system drug-transfer device (CSTD) provides supplemental containment. It does not replace the C-PEC required for hazardous-drug compounding.
CSTDs should be used during hazardous-drug compounding when the dosage form allows and are required for administration of antineoplastic hazardous drugs when the dosage form allows.
Environmental Monitoring and Wipe Sampling
Environmental wipe sampling helps determine whether hazardous-drug containment remains effective. USP <800> recommends an initial benchmark followed by routine testing at least every six months, or more often when necessary.
Potential sample locations include:
- inside the C-PEC;
- pass-through chambers;
- work and staging areas near the C-PEC;
- floors directly beneath or adjacent to the C-PEC;
- areas immediately outside the HD buffer room or C-SCA; and
- patient administration areas.
If measurable contamination is found, the cause should be investigated, documented, contained, and followed by appropriate deactivation, decontamination, cleaning, retraining, or engineering-control improvement. A structured CAPA new process can support this work.
Personal Protective Equipment for Hazardous Drugs
PPE is one layer of hazardous-drug protection and should not be considered a substitute for engineering controls.
For sterile and nonsterile hazardous-drug compounding, the chapter requires protective garments including gowns, head and hair covers, shoe covers, and two pairs of chemotherapy gloves.
Chemotherapy Gloves
When chemotherapy gloves are required, they must meet ASTM D6978 or its successor. They should be powder-free, inspected before use, and changed when damaged or contaminated. For sterile compounding, the outer chemotherapy glove must be sterile.
Protective Gowns
Hazardous-drug gowns should be disposable and resistant to drug permeability. They should close in the back, have long sleeves, and include closed cuffs. Absorbent garments such as cloth laboratory coats are not suitable protective outerwear for HD handling.
Eye, Face and Respiratory Protection
Appropriate eye and face protection should be used when splash exposure is possible. A standard surgical mask does not provide adequate respiratory protection against hazardous-drug exposure. When respiratory protection is required, respirator selection, fit testing, and training should match the expected hazard.
Hazard Communication and Personnel Training
A written hazard-communication system should address labeling, transport, storage, disposal, and access to Safety Data Sheets.
Personnel must be trained before independently handling hazardous drugs. Competency should be reassessed at least every 12 months and training should also occur when new hazardous drugs, equipment, processes, or significant SOP changes are introduced.
Receiving Hazardous Drugs Safely
Receiving personnel should visually inspect shipping containers for damage or leakage and follow written procedures for damaged packages. Chemotherapy gloves should be worn during unpacking, and a spill kit should be accessible in the receiving area.
Damaged packages should be treated as hazardous-drug spill situations and managed through established procedures.
Labeling, Packaging and Transport
Packaging should protect hazardous drugs from damage, leakage, contamination, and degradation while also protecting healthcare workers involved in transport.
Pneumatic tube systems must not be used for liquid hazardous drugs or antineoplastic hazardous drugs because breakage may cause widespread contamination.
Dispensing Hazardous Drugs
Final dosage forms that do not require further manipulation may present lower exposure risk than drugs being crushed, divided, or otherwise altered.
Equipment used for hazardous drugs should be appropriately dedicated and decontaminated after use. Antineoplastic tablets and capsules should not be placed in automated counting or packaging machines where mechanical stress could generate contamination.
Hazardous Drug Compounding
Hazardous-drug compounding must take place within suitable containment engineering controls. Powder-generating activities such as crushing tablets, opening capsules, or weighing hazardous-drug powders require particular attention because particles may become airborne.
Sterile and nonsterile compounding should also comply with the applicable compounding requirements referenced by USP.
Safe Administration of Hazardous Drugs
Administration procedures should use protective devices and techniques that reduce leakage and open-system exposure. For antineoplastic hazardous drugs, CSTDs are required during administration when the dosage form permits their use.
Personnel should avoid unnecessary manipulation such as crushing hazardous tablets or opening capsules. Where manipulation cannot be avoided, suitable PPE and containment practices should be used.
Deactivation, Decontamination, Cleaning and Disinfection
| Step | Main Purpose |
|---|---|
| Deactivation | Render a hazardous compound inactive or less hazardous |
| Decontamination | Remove hazardous-drug residue from a surface |
| Cleaning | Remove organic and inorganic material |
| Disinfection | Destroy microorganisms where sterile operations are performed |
Areas where hazardous drugs are handled and reusable equipment should undergo suitable deactivation, decontamination, and cleaning. Sterile compounding areas require subsequent disinfection.
Written cleaning procedures should define the agents used, dilution where applicable, frequency, method, and documentation requirements.
Hazardous Drug Spill Control
Hazardous-drug spills should be controlled by trained personnel using appropriate PPE, equipment, and established procedures.
A complete spill-response program should define:
- who is responsible for spill response;
- where spill kits are located;
- required PPE;
- cleanup and decontamination steps;
- waste disposal;
- incident documentation; and
- medical evaluation following significant personnel exposure.
Documentation and SOP Requirements
Written procedures should address receiving, storage, compounding, PPE, engineering controls, environmental monitoring, transport, administration, cleaning, spill control, waste disposal, training, and medical surveillance.
Records should be clear, traceable, and reliable. Applying ALCOA+ principles to training, cleaning, monitoring, and corrective-action records strengthens the compliance system.
Organizations subject to broader regulatory frameworks can also align documentation with applicable 21 CFR requirements where relevant.
Medical Surveillance
Medical surveillance provides an occupational-health layer for personnel who routinely handle hazardous drugs. It does not replace engineering controls, PPE, safe work practices, or training.
A medical surveillance program should be designed by qualified occupational-health professionals according to applicable institutional and regulatory requirements.
Practical USP 800 Compliance Checklist
- Maintain and review a current hazardous-drug list at least annually.
- Document applicable assessments of risk.
- Assign a qualified designated person to oversee the program.
- Ensure receiving, storage, and compounding areas meet containment requirements.
- Use suitable C-PECs and C-SECs.
- Maintain required negative pressure and air-change conditions.
- Provide and correctly use appropriate PPE.
- Conduct initial and recurring competency-based training.
- Include environmental wipe sampling in the monitoring program.
- Control damaged packages, leaks, and spills through written procedures.
- Document deactivation, decontamination, cleaning, and disinfection.
- Keep spill kits available in appropriate locations.
- Segregate and dispose of hazardous-drug waste appropriately.
- Maintain reliable SOPs and supporting records.
- Establish occupational-health and medical-surveillance arrangements where applicable.
Key Takeaways
- USP <800> is a complete hazardous-drug exposure-control framework, not only a PPE standard.
- Hazardous-drug risks can occur during receiving, storage, compounding, administration, cleaning, transport, and waste handling.
- Engineering controls, negative pressure, PPE, training, environmental monitoring, and documentation work together as layers of protection.
- Assessments of risk and hazardous-drug lists require regular documented review.
- Environmental contamination should trigger investigation and corrective action.
Conclusion
Effective USP 800 hazardous drug handling depends on combining facility design, engineering controls, safe work practices, PPE, training, environmental monitoring, cleaning, spill control, and documentation into one coordinated safety program.
Organizations should understand which hazardous drugs they handle, evaluate activities that create exposure, maintain suitable containment conditions, train personnel, respond to contamination, and routinely verify that controls remain effective.
The official USP chapter should remain the primary compliance reference, supported by current NIOSH information, occupational-safety requirements, institutional procedures, and applicable local regulations.
Frequently Asked Questions
1. What is USP 800?
USP <800> is a United States Pharmacopeia general chapter that establishes standards for handling hazardous drugs in healthcare settings.
2. What is the main purpose of USP 800?
Its main purpose is to reduce hazardous-drug exposure risks for healthcare workers, patients, and the environment.
3. How often should the hazardous drug list be reviewed?
The entity's hazardous-drug list should be reviewed at least every 12 months. New drugs and dosage forms should also be assessed when introduced.
4. What is an assessment of risk under USP 800?
It is a documented evaluation of factors such as hazardous-drug type, dosage form, exposure potential, packaging, and manipulation to determine whether alternative containment strategies may be appropriate.
5. What is the difference between a C-PEC and C-SEC?
A C-PEC is the primary engineering control where hazardous drugs are directly manipulated. A C-SEC is the room containing the C-PEC and providing secondary containment.
6. What pressure is required for hazardous drug compounding rooms?
Applicable hazardous-drug compounding rooms use negative pressure between approximately 0.01 and 0.03 inches of water column relative to adjacent areas.
7. Are two pairs of chemotherapy gloves required?
Two pairs are required for sterile and nonsterile hazardous-drug compounding and for administration of injectable antineoplastic hazardous drugs.
8. Can a CSTD replace a biological safety cabinet?
No. A CSTD is a supplemental containment control and does not replace the required containment primary engineering control.
9. How often should hazardous drug wipe sampling be performed?
USP <800> recommends an initial benchmark followed by routine wipe sampling at least every six months, or more often when needed.
10. Is USP 800 limited to chemotherapy compounding?
No. It covers receiving, storage, compounding, dispensing, administration, transport, cleaning, spill control, waste handling, training, and medical surveillance.
.webp)
